Elsevier

Life Sciences

Volume 57, Issue 4, 16 June 1995, Pages 371-378
Life Sciences

Anti-inflammatory effects of kappa-opioids in adjuvant arthritis

https://doi.org/10.1016/0024-3205(95)00296-IGet rights and content

Abstract

Current therapies for arthritis are unsatisfactory and cause serious side effects and morbidity. It has been postulated that opioid drugs may block inflammatory mediators and attenuate the joint damage in adjuvant arthritis. However, the importance of opioid receptor subtypes involved in inflammation remains to be determined because data are conflicting in this regard. The present investigation was designed to test the effects of both a kappa-agonist, (±)U50488H and a kappaantagonist, MR2266 on the progression of experimental arthritis. To produce adjuvant arthritis, male Lewis rats were innoculated subcutaneously (s.c.) with 0.05 ml of Freund's complete adjuvant (10 mg/ml) into the right hind paw. The kappa-opioid agonist, (±)U50488H (20 mg/kg/d s.c.) and the kappa-opioid antagonist, MR2266 (20 mg/kg/d s.c.) were administered for 3 days during the primary inflammatory phase of adjuvant arthritis. There were four treatment groups; group I were non-arthritic controls and received paraffin oil vehicle and opioid injections; group II were arthritic controls and received adjuvant and saline injections; group III received adjuvant and agonist and group IV received adjuvant and antagonist. The progression of adjuvant arthritis from day 0 to 24 was monitored by body weight change, hind limb size (ipsilateral and contralateral) and a total severity score for each clinical observation of gait, coat and limb condition. On day 24 histology and radiography of the contralateral limb was performed. There was less soft-tissue swelling, as judged by time-averaged % change in the volume of the contralateral limb, in both agonist (mean ± se: 82 ± 5) and antagonist (77 ± 4) treated rats compared to untreated arthritic controls (99 ± 5, p < 0.05). Other clinical measures of severity were not different between untreated and opioidtreated arthritic rats. However, the joint damage as judged by radiography was lower in kappa agonist treated rats (2.6 ± 0.5, p < 0.05) compared to untreated controls (4.1 ± 0.5) and antagonist treatment (4.4 ± 0.5). Microscopic pathological scores were also significantly lower in agonist (2.8 ± 0.3, p < 0.05) compared to both antagonist treated rats (4.2 ± 0.1) and vehicle-treated controls (3.6 ± 0.2). The results of this study show that kappa-opioid receptor agonists but not antagonists attenuate the progression of experimental arthritis. These observations have important implications for the evaluation and use of kappa-opioid agents in the management of arthritis.

References (34)

  • M.J. Millan et al.

    Neuroscience

    (1991)
  • G.B. Stefano

    Prog. Neurobiol

    (1989)
  • R.A. Lahti et al.

    Life Sci.

    (1982)
  • S.H. Ferreira et al.

    Prostaglandins

    (1979)
  • A.H.S. Hassan et al.

    Neuroscience Letters

    (1992)
  • E. Weihe et al.

    Progress in Brain Research

    (1988)
  • R. Oku et al.

    Neurosci. Lett.

    (1987)
  • F. Lembeck et al.

    Neuropeptides

    (1981)
  • G.F. Costello et al.

    Eur. J. Pharmacol.

    (1988)
  • C. Heath et al.

    J. Rheumatol

    (1995)
  • T. Pincus et al.

    British Journal of Rheumatology

    (1993)
  • T. Pincus et al.

    Journal of Rheumatology

    (1992)
  • T. Pincus et al.

    Journal of Rheumatology

    (1992)
  • J.D. Levine et al.

    J. Immunol.

    (1985)
  • J.S. Walker et al.
  • M.J. Iadorola et al.

    Brain Res.

    (1988)
  • E.T. Wei et al.

    J. Pharmacol. Exp. Ther

    (1986)
  • Cited by (26)

    • Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis

      2019, European Journal of Pharmacology
      Citation Excerpt :

      IL-10 downregulates expression of Th1 cytokines like IL-2 and interferon-γ (IFN-γ), limits pro-inflammatory cytokine release (Tumor Necrosis Factor-α (TNF-α), IL-1, IL-6, IL-12), and controls differentiation of macrophages, T and B cells (Couper et al., 2008; Shachar and Karin, 2013). The anti-inflammatory effect of kappa opioid agonists has been reported in inflammatory pain models in rats (Walker et al., 1995; Binder et al., 2001; Walker, 2003; Bileviciute-Ljungar et al., 2006) and in mice (Paton et al., 2017). Also, Bastos et al. (2011) showed that U-50,488 (a kappa opioid receptor agonist) reduced bone loss and IL-6 levels and increased IL-10 in ligature-induced periodontal disease in rats.

    • Peripheral kappa and delta opioid receptors are involved in the antinociceptive effect of crotalphine in a rat model of cancer pain

      2013, Pharmacology Biochemistry and Behavior
      Citation Excerpt :

      In vitro studies are now in progress in order to characterize the possible direct effect of crotalphine on CB2 cannabinoid receptors. It is well demonstrated that, in addition to analgesia, κ-opioid receptor agonists, including peripherally selective agonists, display potent anti-inflammatory actions (Walker et al., 1995; Wie et al., 1998; Catheline et al., 1999; Binder et al., 2001). Therefore, a possible anti-inflammatory activity of crotalphine, which may contribute to its antinociceptive action, cannot be ruled out.

    • Sex-specificity and estrogen-dependence of kappa opioid receptor-mediated antinociception and antihyperalgesia

      2010, Pain
      Citation Excerpt :

      In contrast, greater antinociception in males in response to KOR-agonists has also been reported [31,35,37,41]. Similarly, conflicting findings have emerged from studies in chronic pain models [5,7,8,45–47]. These contradictory findings may result from several variables including dose, route of drug delivery, nociceptive assay, stimulus intensity, estrous cycle stage, and species and strain of animals tested.

    View all citing articles on Scopus
    View full text